A prospective randomized trial of urokinase as an adjuvant in the treatment of proven hickman catheter sepsis

https://doi.org/10.1016/S0022-3468(98)90194-4Get rights and content

Abstract

Background/Purpose: Chronic vascular access catheters have become an important adjunct to the treatment of children with complex medical diseases, particularly malignancy. One of the major complications of chronic venous access devices is bacterial infection of the catheter site and bloodstream. Infusion of systemic antibiotics directly into the catheter has been the standard initial therapy with failure leading to catheter removal and replacement. It has been suggested by a number of investigators that the addition of urokinase as a thrombolytic agent to lyse any accumulated thrombus or fibrin would increase the successful catheter clearance by antibiotics. This study was designed as a prospective, randomized trial to compare treatment of children with positive catheter blood cultures with either antibiotics alone or in combination with urokinase 5,000 U boluses 12 and 24 hours after study entry.

Methods: A total of 63 patients were entered in the study. Thirty-three received antibiotics and urokinase, and 30 received antibiotics alone.

Results: A total of 45 catheters (71%) were cleared of infection and salvaged. Treatment failures leading to catheter removal occurred in 9 of 33 in the experimental group and 9 of 30 in the control population (no significant difference).

Conclusions: Urokinase could not be shown to act as an adjuvant in the clearance of infection from chronic central venous access catheters that had no evidence of clot or thrombus. This study required the performance of a dye study and excluded any patient with a known thrombus. This conclusion must therefore be limited to patients with no evidence of a clot or fibrin sheath.

References (5)

There are more references available in the full text version of this article.

Cited by (32)

  • HEALTH CARE–ASSOCIATED INFECTIONS

    2009, Feigin and Cherry's Textbook of Pediatric Infectious Diseases, Sixth Edition
  • Treatment of Dialysis Catheter-Related Staphylococcus aureus Bacteremia With an Antibiotic Lock: A Quality Improvement Report

    2007, American Journal of Kidney Diseases
    Citation Excerpt :

    Conversely, a previous study reported a 2-fold greater risk of serious complications with methicillin-resistant S aureus catheter-related bacteremia.15 A number of studies reported a 62% to 100% success rate of an antibiotic lock in salvaging the catheter in patients with bacteremia related to tunneled catheters used for dialysis, chemotherapy, or total parenteral nutrition.5-8,17-21 This approach was endorsed by the Infectious Diseases Society of America for the management of selected patients with catheter-related bacteremia.22

  • Dialysis catheter-related bacteremia: Treatment and prophylaxis

    2004, American Journal of Kidney Diseases
    Citation Excerpt :

    In a randomized study of children with Hickman catheters and catheter-related bacteremia, 63 patients received an antibiotic lock, with or without the addition of intraluminal urokinase. Infection-free survival was similar in both groups (73% versus 70%), suggesting no benefit to urokinase instillation as an adjunct to the antibiotic lock.40 In a second nonrandomized study of children with Broviac catheters and catheter-related bacteremia, infection-free survival was greater for those with systemic antibiotic therapy in conjunction with an ethanol lock compared with systemic antibiotic therapy alone (67% versus 47%).41

  • Diagnosis and Management of Long-term Central Venous Catheter Infections

    2004, Journal of Vascular and Interventional Radiology
  • Infectious complications of venous access devices

    2002, Techniques in Vascular and Interventional Radiology
    Citation Excerpt :

    Although early reports suggest that concurrent thrombolytic and antibiotic therapy may be beneficial in treating catheter-related infection,63 more recent investigations suggest that such therapy is not routinely efficacious. In a study of 63 patients, Atkinson et al demonstrated no benefit to the routine use of urokinase in combination with antibiotic therapy in the absence of documented pericatheter thrombosis or fibrin sheath.64 The authors suggested that thrombolytic therapy be reserved for use in patients with contrast study documentation of pericatheter clot or fibrin sheath.

View all citing articles on Scopus
View full text